Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426(6965): 450-454. [DOI: 10.1038/nature02145]
Zisman LS. ACE and ACE2: a tale of two enzymes. Eur Heart J 2005; 26(4): 322-324. [DOI: 10.1093/eurheartj/ehi043]
Pagliaro P, Penna C. ACE/ACE2 Ratio: A Key Also in 2019 Coronavirus Disease (Covid-19)? Front Med (Lausanne) 2020; 7(335. [DOI: 10.3389/fmed.2020.00335]
Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, et al. Two Putative Active Centers in Human Angiotensin I-Converting Enzyme Revealed by Molecular Cloning. Proc Natl Acad Sci USA 1988; 85(24): 9386-9390.
Wei L, Clauser E, Alhenc-Gelas F, Corvol P. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem 1992; 267(19): 13398-13405.
Bernstein KE, Ong FS, Blackwell WL, Shah KH, Giani JF, Gonzalez-Villalobos RA, et al. A Modern Understanding of the Traditional and Nontraditional Biological Functions of Angiotensin-Converting Enzyme. Pharmacol Rev 2013; 65(1): 1-46.
Jackson L, Eldahshan W, Fagan S, Ergul A. Within the Brain: The Renin Angiotensin System. Int J Mol Sci 2018; 19(3): 876.
Johansson B, Holm M, Ewert S, Casselbrant A, Pettersson A, Fändriks L. Angiotensin II type 2 receptor-mediated duodenal mucosal alkaline secretion in the rat. Am J Physiol-Gastroint Liver Physiol 2001; 280(6): G1254-G1260. [DOI: 10.1152/ajpgi.2001.280.6.G1254]
Paul M, Mehr AP, Kreutz R. Physiology of Local Renin-Angiotensin Systems. Physiol Rev 2006; 86(3): 747-803. [DOI: 10.1152/physrev.00036.2005]
Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003; 35(6): 881-900. [DOI: 10.1016/S1357-2725(02)00271-6]
Pauls K, Metzger R, Steger K, Klonisch T, Danilov S, Franke FE. Isoforms of angiotensin I-converting enzyme in the development and differentiation of human testis and epididymis. Andrologia 2003; 35(1): 32-43.
Cushman DW, Cheung HS. Concentrations of angiotensin-converting enzyme in tissues of the rat. Biochim Biophys Acta Enzymol 1971; 250(1): 261-265. [DOI: 10.1016/0005-2744(71)90142-2]
Zhou Z, Cheng C, Li Y. Structure-based design and optimization of antihypertensive peptides to obtain high inhibitory potency against both renin and angiotensin I-converting enzyme. SAR QSAR Environ Res 2015; 26(12): 1001-1016. [DOI: 10.1080/1062936X.2015.1104725]
Guy JL, Lambert DW, Warner FJ, Hooper NM, Turner AJ. Membrane-associated zinc peptidase families: comparing ACE and ACE2. Biochim Biophys Acta 2005; 1751(1): 2-8. [DOI: 10.1016/j.bbapap.2004.10.010]
Guy JL, Jackson RM, Acharya KR, Sturrock ED, Hooper NM, Turner AJ. Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence. Biochemistry 2003; 42(45): 13185-13192. [DOI: 10.1021/bi035268s]
Cui H-T, Yu-Ting L, Li-Ying G, Xiang-Guo L, Lu-Shan W, Jian-Wei J, et al. Traditional Chinese medicine for treatment of coronavirus disease 2019: a review. Trad Med Res 2020; 5(2): 65-73.
Fraga-Silva RA, Costa-Fraga FP, Murca TM, Moraes PL, Martins Lima A, Lautner RQ, et al. Angiotensin-converting enzyme 2 activation improves endothelial function. Hypertension 2013; 61(6): 1233-1238. [DOI: 10.1161/HYPERTENSIONAHA.111.00627]
Prada JAH, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RAS, et al. Structure-Based Identification of Small-Molecule Angiotensin-Converting Enzyme 2 Activators as Novel Antihypertensive Agents. Hypertension 2008; 51(5): 1312-1317. [DOI: doi:10.1161/HYPERTENSIONAHA.107.108944]
Velkoska E, Patel SK, Burrell LM. Angiotensin con-verting enzyme 2 and diminazene: role in cardio-vascular and blood pressure regulation. Curr Opin Nephrol Hypert 2016; 25(5): 384-395. [DOI: 10.1097/MNH.0000000000000254]
Huang L, Sexton DJ, Skogerson K, Devlin M, Smith R, Sanyal I, et al. Novel peptide inhibitors of angiotensin-converting enzyme 2. J Biol Chem 2003; 278(18): 15532-15540. [DOI: 10.1074/jbc.M212934200]
Moccia F, Gerbino A, Lionetti V, Miragoli M, Munaron LM, Pagliaro P, et al. COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches. Geroscience 2020; 42(4): 1021-1049. [DOI: 10.1007/s11357-020-00198-w]
Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med 2020; 27(3):1-2. [DOI: 10.1093/jtm/taaa041]
Arai T, Sekizawa K, Ohrui T, Fujiwara H, Yoshimi N, Matsuoka H, et al. ACE inhibitors and protection against pneumonia in elderly patients with stroke. Neurology 2005; 64(3): 573-574. [DOI: 10.1212/01. wnl.0000150897.14961.0f]
aldeira D, Alarcão J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. Br Med J 2012; 345(e4260. [DOI: 10.1136/bmj.e4260]
Sekizawa K, Matsui T, Nakagawa T, Nakayama K, Sasaki H. ACE inhibitors and pneumonia. Lancet 1998; 352(9133): 1069. [DOI: 10.1016/S0140-6736(05)60114-6]
Flacco ME, Acuti Martellucci C, Bravi F, Parruti G, Cappadona R, Mascitelli A, et al. Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis. Heart 2020; 106(19): 1519-1524. [DOI: 10.1136/heartjnl-2020-317336]
Hippisley-Cox J, Young D, Coupland C, Channon KM, Tan PS, Harrison DA, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart 2020; 106(19): 1503-1511. [DOI: 10.1136/heartjnl-2020-317393]
Guo J, Huang Z, Lin L, Lv J. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Am Heart Assoc 2020; 9(7): e016219. [DOI: 10.1161/JAHA.120.016219]
Pergolizzi JV, Varrassi G, Magnusson P, LeQuang JA, Leopoulou M, Paladini A, et al. The concern about ACE/ARB and COVID-19: Time to hold your horses! J Am Pharm Ass 2020; 60(6): e88-e90. [DOI: 10.1016/j. japh.2020.06.026]
Rossi GP, Sanga V, Barton M. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. eLife 2020; 9(e57278. [DOI: 10.7554/eLife.57278]
Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. Am J Hypert 2020; 33(5): 373-374. [DOI: 10.1093/ajh/hpaa057]
Sommerstein R, Kochen MM, Messerli FH, Gräni C. Coronavirus Disease 2019 (COVID‐19): Do Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? J Am Heart Ass 2020; 9(7): e016509. [DOI: doi:10.1161/JAHA.120.016509]
South AM, Tomlinson L, Edmonston D, Hiremath S, Sparks MA. Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol 2020; 16(6): 305-307. [DOI: 10.1038/s41581-020-0279-4]
Sriram K, Insel PA. Risks of ACE Inhibitor and ARB Usage in COVID-19: Evaluating the Evidence. Clin Pharmacol Ther 2020; 108(2): 236-241. [DOI: 10.1002/cpt.1863]
Tetlow S, Segiet-Swiecicka A, O’Sullivan R, O’Halloran S, Kalb K, Brathwaite-Shirley C, et al. ACE-Inhibitors, Angiotensin Receptor Blockers and Endothelial Injury in COVID-19. J Intern Med 2020. [DOI: 10.1111/joim.13202]
Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med 2020; 382(17): 1653-1659. [DOI: 10.1056/NEJMsr2005760]
Wang JJ, Edin ML, Zeldin DC, Li C, Wang DW, Chen C. Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities. Pharmacol Ther 2020; 215(107628. [DOI: 10.1016/j. pharmthera.2020.107628]
Wang K, Gheblawi M, Oudit GY. Angiotensin Converting Enzyme 2: A Double-Edged Sword. Circulation 2020.[DOI: 10.1161/CIRCULATIONAHA.120.047049]
Zhang P, Zhu L, Cai J, Lei F, Qin J-J, Xie J, et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res 2020; 126(12): 1671-1681. [DOI: 10.1161/CIRCRESAHA.120.317134]
Leclézio A, Robinso J, Banerjee I. SARS-CoV-2: ACE inhibitors, disastrous or desirable? J Biomed Sci 2020; 7(1): 40-46. [DOI: 10.3126/jbs.v7i1.29852]
Koshy AN, Murphy AC, Farouque O, Ramchand J, Burrell LM, Yudi MB. Renin–angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis. Intern Med J 2020; 1-7. [DOI: 10.1111/imj.15002]
Battistoni A, Volpe M. Might renin–angiotensin system blockers play a role in the COVID-19 pandemic? Eur Heart J Cardiovasc Pharmacother 2020; 6(4): 248-251.[DOI: 10.1093/ehjcvp/pvaa030]
Froldi G. What could be the better choice between ACE inhibitors and AT1R antagonists in coronavirus disease 2019 (COVID-19) patients? J Med Virol 2020; 92(11): 2302-2303. [DOI: 10.1002/jmv.25974]
Messerli FH, Siontis GCM, Rexhaj E. COVID-19 and Renin Angiotensin Blockers: Current Evidence and Recommendations. Circulation 2020; 141(25): 2042-2044. [DOI: 10.1161/CIRCULATIONAHA.120.047022]
Aitken RJ. COVID-19 and human spermatozoa—Potential risks for infertility and sexual transmission?Andrology 2020; n/a(n/a): 1-5. [DOI: 10.1111/andr.12859]
Anifandis G, Messini CI, Daponte A, Messinis IE. COVID-19 and fertility: a virtual reality. Reprod BioMed Online 2020; 41(2): 157-159. [DOI: 10.1016/j. rbmo.2020.05.001]
Ojaghi M, Kastelic J, Thundathil J. Testis-specific isoform of angiotensin-converting enzyme (tACE) is involved in the regulation of bovine sperm capacitation. Mol Reprod Dev 2017; 84(5): 376-388. [DOI: doi:10.1002/mrd.22790]
Gianzo M, Urizar-Arenaza I, Muñoa-Hoyos I, Larreategui Z, Garrido N, Casis L, et al. Human sperm testicular angiotensin-converting enzyme helps determine human embryo quality. Asian J Androl 2018; 20(5): 498-504. [DOI: 10.4103/aja.aja_25_18]
Foresta C, Rocca MS, Di Nisio A. Gender susceptibility to COVID-19: a review of the putative role of sex hormones and X chromosome. J Endocrinol Invest 2020. [DOI: 10.1007/s40618-020-01383-6]
Wang Z, Xu X. scRNA-seq Profiling of Human Testes Reveals the Presence of the ACE2 Receptor, A Target for SARS-CoV-2 Infection in Spermatogonia, Leydig and Sertoli Cells. Cells 2020; 9(4). [DOI: 10.3390/cells9040920]
Reis FM, Bouissou DR, Pereira VM, Camargos AF, dos Reis AM, Santos RA. Angiotensin-(1-7), its receptor Mas, and the angiotensin-converting enzyme type 2 are expressed in the human ovary. Fert Steril 2011; 95(1):176-181. [DOI: 10.1016/j.fertnstert.2010.06.060]
Email this article (Login required) 
